A Fresh Look at CAR T-Cell Therapy: Recent Advances, New Evidence, and Evolving Paradigms to Improve Patient Care

Gain expert insights into best practices and emerging strategies in CAR T-cell therapy for patients with leukemia, lymphoma, and myeloma with this dynamic online educational program based on a live Webinar. Download slides with all the key data, watch the on-demand Webcast, and join the conversation around an expert-authored commentary.
Renier J. Brentjens, MD, PhD
Program Director
Renier J. Brentjens, MD, PhD
Frederick L. Locke, MD
Noopur Raje, MD
Michael Wang, MD

ClinicalThought

CAR T-cell therapies continue to generate excitement for clinicians and patients with hematologic malignancies. In this commentary, I outline key recent advances and key upcoming clinical research to be presented at ASH 2020.

Michael Wang, MD Released: December 1, 2020

Downloadable Slidesets

Download this short summary slideset of key takeaway points from a live presentation on current best practices and emerging strategies in the use of CAR T-cell therapy for patients with hematologic malignancies.

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: December 8, 2020

Download this slideset for an overview of CAR T-cell therapy and expert perspectives on current best practices and emerging strategies in the use of CAR T-cell therapy for patients with ALL.

Renier J. Brentjens, MD, PhD Released: December 3, 2020

Download this slideset for expert perspectives on current best practices and emerging strategies in the use of CAR T-cell therapy for patients with lymphomas and CLL.

Frederick L. Locke, MD Released: December 3, 2020

Download this slideset for expert perspectives on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma, as well as a discussion of management of key toxicities associated with CAR T-cell therapy.

Noopur Raje, MD Released: December 3, 2020

On Demand Webcast

In this interactive on-demand Webcast, expert faculty members discuss how they currently use CAR T-cells to treat hematologic malignancies and provide a look ahead at new data and promising agents that may soon change practice.

Renier J. Brentjens, MD, PhD
Program Director
Frederick L. Locke, MD Noopur Raje, MD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.75 Medical Knowledge MOC point(s) Released: December 8, 2020 Expired: December 7, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue